Program
itareparib
Its studies are mostly in Ovarian Neoplasms · Small Cell Lung Carcinoma · Glioblastoma · Carcinoma, Ovarian Epithelial, led by Nerviano Medical Sciences.
Furthest: phase 2, since May 21, 20214 company-led studies, 2 open or runningNext primary completion: May 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nerviano Medical Sciences | 42 open or running | phase 2since May 21, 2021 | Nov 12, 2019 | May 30, 2027phase 2 · NCT04910022 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 12, 2019First study: phase 1 study in Carcinoma, Ovarian EpithelialFirst studyNCT04182516 · 52 enrolled · United States, Bulgaria, China and more
- May 21, 2021Phase 2 study in GlioblastomaNCT04910022 · 150 enrolled · United States, Italy, Netherlands and more
- Apr 4, 20252 phase 1 studiesNCT06931626, NCT06930755
Ahead
- May 30, 2027Primary completion: phase 2 study in GlioblastomaNCT04910022
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06930755Ovarian Neoplasms · United States | 1 | Terminated | Aug 17, 2026 | 1 |
| NCT06931626Small Cell Lung Carcinoma · United States | 1 | Recruiting | Oct 30, 2026 | 10 |
| NCT04910022Glioblastoma · United States, Italy, Netherlands and more | 2 | Active, not recruiting | May 30, 2027 | 150 |
| NCT04182516Carcinoma, Ovarian Epithelial · United States, Bulgaria, China and more | 1 | Terminated | Mar 31, 2023 | 52 |
How it is read
Names in the registry
- “NMS-03305293”, 4 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 1 study
- Small Cell Lung Carcinoma, 1 study
- Glioblastoma, 1 study
- Carcinoma, Ovarian Epithelial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.